Benzinga Money is a reader-supported publication. We may earn a commission from the advertisers associated with this article. Read our Advertiser Discloser.
Surgical imaging is a key part of any operation, as it provides surgeons with internal images to get a better idea of a patient’s condition. These images, however, come at a price. Traditional 3D imaging exposes patients to high doses of radiation and can be time-consuming, whereas 2D imaging uses less radiation but provides a less precise picture.
One medical company is looking to change that, and has already been successful in doing so at some of the nation’s top hospitals.
nView medical is advancing surgical imaging with AI-powered image generation technology focused on precision, efficiency, and safety. The FDA-cleared nView s1 system has been used in over 500 surgeries across leading U.S. hospitals, with the goal of reducing radiation exposure and enhancing accuracy.
The company is backed by $8.5 million in venture capital, grant, and angel investor funding, a leadership team with decades of med-tech experience, and eight granted patents.
Providing New Imaging to Surgeons Across the U.S.
The awareness that radiation emitted from imaging devices is a concern for doctors and patients is increasing, especially when dealing with children and with 3D imaging. Since its early days, Utah-based nView medical focused its mission to make pediatric surgeries safer, faster, and consistently accurate.
In 2019, the FDA cleared the company’s first imaging device, the nView s1 system. It uses 5.5 times less radiation than typical 3D imaging, and eliminates the need for rotating scanners. This speeds up the process for doctors, leading to improved patient care and outcomes.
The first pediatric spinal surgery using the system was performed in late 2020 at Children’s National Hospital in Washington DC. It’s now being used in top-tier pediatric hospitals across the US, like Stanford Children’s, Texas Scottish Rite, and St. Louis Children’s. The company recently celebrated its 500th operation.
“I still vividly remember our first surgery using our system,” nView medical Founder Cristian Atria said after the 500th surgery performed with the nView s1. “That experience reinforced our mission to make surgeries safer for patients, and reminded me why we started this venture. Now that we have surpassed 500 surgeries with the nView s1, it feels that our mission is becoming a reality!"
After proving itself in the $250 million pediatric surgical imaging market with more than $1 million in revenue, the company announced in April 2024 its first adult spinal surgery using the technology and now plans to expand into the $6 billion U.S. adult surgical market. There’s also a potential to break into the broader $10 billion X-ray and CT medical imaging market.
Join the AI Imaging Revolution
Already backed by millions of dollars in grants and private funding, nView medical is now opening to everyday investors who believe in the company’s vision of transforming surgeries in operating rooms everywhere.
“Now, for the first time, anyone can be part of this journey, helping us expand access to AI-powered low-dose 3D imaging technology,” Atria says.
The company, which has a $30 million valuation, is looking to raise funds1 to accelerate its research and development and commercialization.
Invest in nView today and be part of the transformation in surgical imaging.
Disclaimers
Please be advised that alternative investments carry a risk of monetary loss. Neither Benzinga nor its staff recommends that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. All information contained on this website is provided as general commentary for informative and entertainment purposes and does not constitute investment advice.
Benzinga will not accept liability for any loss or damage, including without limitation to, any loss of profit, which may arise directly or indirectly from use of or reliance on this information, whether specifically stated in the above Terms of Service or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.
1 Offering is made available through StartEngine Primary, LLC via Reg CF. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and the issuer. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. Benzinga may receive monetary compensation from the issuer for publicizing the offering of the issuer’s securities.
This content is for informational purposes only and is not intended to be investing advice.
About Anthony O'Reilly
Anthony O’Reilly is an updates editor for Benzinga. He’s won numerous journalism awards for his coverage of the New York City economy and Long Island school district budgets.
